Biogen Pushes Ahead With Aduhelm Confirmatory Trial As CMS Final Decision Looms
Executive Summary
Biogen interim head of R&D Priya Singhal talked to the Pink Sheet about ramping up the Phase IV trial for Aduhelm, the CMS coverage determination and taking over R&D at a challenging time for the company.
You may also be interested in...
Earlier CMS Review Could Improve Drug Labels, Ex-FDA Official Says
US FDA’s recently retired Cell and Gene Therapy leader said when CMS engaged with him it was often due to ‘ambiguities’ in drug labels that made it harder for the payer to make its coverage decision. Can earlier discussions smooth Medicare and private-market coverage?
Aduhelm’s Goodbye: ENVISION Confirmatory Study To End In May, With BLA Withdrawal In November
Biogen faces complex logistics in shutting down a multinational trial with more than 200 sites and approximately 1,000 patients enrolled; company also is facing calls to publish data collected from the unfinished study as well as other aducanumab trials.
Biogen Closes The Book On The Aduhelm Saga
Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial. Product’s legacy includes an FDA that appears less enthusiastic about accelerated approvals for large indications and a CMS that is more interested in label-driven reimbursement decisions.